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VEGFMesenchymal stem cells are potent candidates in stroke therapy due to their ability to secrete protective anti-
inﬂammatory cytokines and growth factors. We investigated the neuroprotective effects of human placental
mesenchymal-like adherent stromal cells (PLX) using an established ischemic model of nerve growth factor
(NGF)-differentiated pheochromocytoma PC12 cells exposed to oxygen and glucose deprivation (OGD) followed
by reperfusion. Under optimal conditions, 2 × 105 PLX cells, added in a trans-well system, conferred 30–60%
neuroprotection to PC12 cells subjected to ischemic insult. PC12 cell death, measured by LDH release, was
reduced by PLX cells or by conditionedmediumderived fromPLX cells exposed to ischemia, suggesting the active
release of factorial components. Since neuroprotection is a prominent function of the cytokine IL-6 and the angio-
genic factor VEGF165, we measured their secretion using selective ELISA of the cells under ischemic or normoxic
conditions. IL-6 and VEGF165 secretion by co-culture of PC12 and PLX cells was signiﬁcantly higher under ische-
mic compared to normoxic conditions. Exogenous supplementation of 10 ng/ml each of IL-6 and VEGF165 to
insulted PC12 cells conferred neuroprotection, reminiscent of the neuroprotective effect of PLX cells or their
conditioned medium. Growth factors as well as co-culture conditioned medium effects were reduced by 70%
and 20% upon pretreatment with 240 ng/ml Semaxanib (anti VEGF165) and/or 400 ng/ml neutralizing anti IL-6
antibody, respectively. Therefore, PLX-induced neuroprotection in ischemic PC12 cellsmay be partially explained
by IL-6 and VEGF165 secretion. These ﬁndings may also account for the therapeutic effects seen in clinical trials
after treatment with these cells.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Amid various cell therapy strategies for treating neurodegenerative
diseases including brain trauma and ischemic disorders, mesenchymal
stem cells (MSC) transplantation is considered a promising therapeutic
modality [1]. The human placental expanded (PLX) mesenchymal-like
adherent stromal cells, characterized by highly selective expression ofional; ELISA, enzyme-linked im-
isothiocyanate; FU,ﬂuorescence
rleukin 6; LDH, lactate dehydro-
emcells;NGF, nerve growth fac-
d glucose deprivation; PC12,
, Human PLacental eXpanded
ygen species; TBARS, thiobarbi-
-tetramethylpiperidine-1-oxyl;
972 8 9344131.
vin).typical markers such as CD 73 (ecto-5′-nucleotidase), CD 90 (Thy-1
cell surface antigen) and CD 29 (Integrin β-1) [2], have been tested for
their therapeutic effect in experimental models to treat stroke outcome
in rats [2] and limb ischemia in mice [3]. PLX cells at low and high doses
are currently evaluated for therapy in several ischemic disorders and are
used in human clinical trials for treating peripheral artery disease, accel-
erate regeneration of injured gluteal musculature after total hip
arthroplasty and improved intermittent claudication (http://www.
clinicaltrials.gov) due to their pro-angiogenic, immnomodulatory and
reparative beneﬁcial therapeutic effects [2,4]. Compelling evidence
exist thatMSC confer beneﬁcial therapeutic effects after transplantation
alone or together with hematopoietic stem cells [4] through the secre-
tion of immune modulatory and neurotropic factors released in a para-
crine fashion. The paracrine theory is promoting novel pharmacological
outlooks by which neuroprotection of the injured neuronal tissue may
be achieved by the secretome of the transplanted MSC, calling for the
identiﬁcation of particular cytokines, chemokines and growth factors
secreted by MSC and their involvement in neurotherapeutic effects [5].
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culture in a trans-well co-culture system with a rat adrenergic neural
tumor pheochromocytoma cell line PC12 that has been extensively
used as a model for dopaminergic neurons and neuronal differentiation
in general. NGF-differentiated PC12 cells have been subjected to a brief
(4 h) oxygen and glucose deprivation phase (OGD) followed by a
reperfusion phase (18 h) to mimic clinical situations of ischemia in
order to study the possible beneﬁcial effects of PLX cells on this insult.
The feasibility of the PC12 cell model system was validated recently by
our laboratory in diverse insults [6] and found suitable to investigate
the neuroprotective effects of different drugs such as the calcium chan-
nel blockers nifedipine and nimodipine [7], the brain endogenous neu-
roprotective histidine dipeptides carnosine and homocarnosine [8], the
superoxide dismutase mimetic and antioxidant neuroprotective
compound, Tempol [9] and the monoamine oxidase B inhibitor
with neuroprotective effects, used in Parkinson therapy, Rasagiline
[10].
Using the present pharmacological model, we now demonstrate a
robust neuroprotective effect of PLX cells on ischemic PC12 cells and
identify stimulus-secreted speciﬁc cytokines by the former under
ischemic conditions. These ﬁndings should pave the way for alternative
therapeutic options for ischemic disorders using human IL-6 and
VEGF165 recombinant proteins.
2. Materials and methods
2.1. Chemicals, growth factors and antibodies
4-Hydroxy-2, 2, 6, 6-tetramethylpiperidine-1-oxyl (Tempol), thio-
barbituric acid (TBA), butylated hydroxytoluene (BHT), 1, 1, 3, 3-
tetraethoxypropane (TEP) and hydrogen peroxide (H2O2) were pur-
chased from Sigma-Aldrich (St. Louis, MO). NGF was purchased from
Alomone Labs (Jerusalem, Israel). Dulbecco's modiﬁed Eagle's medium
(DMEM), fetal calf serum (FCS), horse serum (HS), penicillin and strep-
tomycin were purchased from Biological Industries (Beit Haemek,
Israel). Collagen type Ι from rat tail was purchased from BD Biosciences
(Bedford, MA, USA). Alamar bluewas purchased from Invitrogen Corpo-
ration (Grand Island, NY, USA). Recombinant human IL-6, recombinant
human VEGF165 and rabbit anti-human IL-6 were purchased from
PeproTech (Rehovot, Israel) while Semaxanib was purchased from
Santa Cruz Biotechnology (Dallas, Texas, USA). Quantikine human IL-6
ELISA kit and quantikine human/mouse VEGF ELISA kit were purchased
from R&D Systems (Minneapolis, MN, USA). Speciﬁc antibodies towards
CD antigens labeled with either FITC or PE: CD29, CD54, CD90 and
CD166, CD44, CD51, CD106 and CD73 were purchased from
Immunotech (Vaudreuil-Dorion, Canada) and Southern Biotech
(Alabama USA), respectively.
2.2. Cell cultures
2.2.1. PC12 pheochromocytoma cultures
PC12 cells were propagated in 25 cm2 ﬂasks in growth medium
composed of Dulbecco's modiﬁed Eagle's medium (DMEM) supple-
mented with 7% fetal calf serum (FCS), 7% horse serum (HS),
10,000 U/ml penicillin and 100 μg/ml streptomycin, as previously de-
scribed [11]. The medium was replaced every second day and cells
were grown at 37 °C, in a humidiﬁed atmosphere of 6% CO2.
2.2.2. PLX cell cultures
PLX cells were manufactured by Pluristem Therapeutics, Ltd. (Haifa,
Israel) [3,4]. Brieﬂy, full term human placentas were collected from
healthy donor mothers following elective cesarian section and after
informed consent in the frame of the Helsinki program. Placental stro-
mal cells isolated from placenta tissue were propagated as two dimen-
sional (2D) cultures followed by 3D culture on ﬁbrous carriers in a
bioreactor [4]. The 3D cultured cells were harvested and cryopreservedin liquid nitrogen. The characterization of PLX cells was performed by
positive labeling with the following conjugated anti-human antibodies:
CD29-FITC, and CD73 (SH3)-FITC and CD105. One day before the exper-
iment, PLX cells from three different donor-derived batches were
thawed and 2× 105 cellswere plated onmembrane of Falcon culture in-
serts (polyethylene terephthalate track-etched membranes, 1 μm pore
size, diameter 12 mm) from Becton Dickinson Co. (Franklin Lakes, NJ,
USA) and grown in DMEM supplemented with 7% FBS, 7% HS,
10,000 U/ml penicillin and 100 μg/ml streptomycin. Cells were main-
tained at 37 °C, in a humidiﬁed atmosphere of 6% CO2. For experiments,
the cells were harvested and adjusted to constant densities using
hemocytometry before plating.
2.3. Ischemic insult protocol using NGF-differentiated PC12 cells
Actively proliferating PC12 cells (2 × 105 cells/well) were seeded
onto 12-well plates pre-coated with 200 μg/ml collagen type-Ι and
differentiated with 50 ng/ml Nerve Growth Factor (NGF) for 7 days.
Fresh medium-containing NGF was added every second day. In all
experiments, only NGF-differentiated PC12 cells were used. On the
day of the experiment, cell medium was replaced to glucose-free
DMEM (hypoglycemic insult) and cultures introduced into an ische-
mic chamber with oxygen level below 1% (anoxic insult) for 4 h at
37 °C under oxygen and glucose deprivation (OGD) as previously de-
scribed [6]. In order, to mimic in vivo reperfusion conditions due to
renewal of blood supply, at the end of the OGD insult, 4.5 mg/ml glu-
cose was added and cultures were incubated for 18 h under normoxic
conditions (reperfusion/reoxygenation) to complete the ischemic in-
sult. Operationally, ischemic insult represents therefore a combina-
tion of both OGD and reperfusion phases. Control cultures were
maintained under regular atmospheric conditions (normoxia) in the
presence of 6% CO2. The antioxidant Tempol was added to appropriate
wells, before the OGD insult, unless otherwise stated [8]. Addition of
PLX cells (2 × 105 cells/well) to the double chamber co-culture system
[6] was routinely performed prior to OGD or whenever stated after
OGD, before reperfusion. At the end of the reperfusion cell death
was measured as detailed below. All experiments (n = 15) were car-
ried out under good laboratory practice conditions using a clean room,
regulated according to ISO7 requirements (10,000 particles/m3).
2.4. Conditioned medium preparation
Cultures of PC12 cells (2 × 105/well) or PLX cells (2 × 105/well) and
co-cultures of both cell lines were exposed to OGD for 4 h followed by
18 h reperfusion. At the end of the ischemic insult the medium was
collected, ﬁltered (0.2 μmWhatman GmbH, Dassel, Germany) and fro-
zen at−20 °C. The ﬁltered medium denoted as “conditioned medium”
was frozen and aliquots were used for designated experiments.
2.5. Determination of cell death by Lactate dehydrogenase (LDH) release
Cell death was evaluated by measuring the leakage of LDH into the
medium as previously described [8]. LDH activity was determined at
340 nm using a spectroﬂuorimeter (TECAN, SPECTRA Fluor PLUS,
Salzburg, Austria). Basal LDH release was measured in both PC12
and PLX cultures maintained under normoxic conditions. Under
OGD insult, LDH release representing cell death was expressed as per-
cent of total LDH released into themedium upon subtracting the basal
values of LDH release. Total LDH (extracellular + intracellular) was
obtained by freezing and thawing the cultures. The neuroprotective
effect, deﬁned as the percent decrease in LDH release in the presence
of PLX cells or Tempol was normalized to untreated ischemic cultures
and is depicted below:
Cell death %ð Þ ¼ ðLDH ischemia – basalð Þ= LDHtotalð Þ  100:
Fig. 1. Cell-density and duration of OGD dependency of LDH release by PC12 cells. PC12
cells were seeded at designated densities in 12-well plates and differentiated for 7 days
in the presence of NGF. Cells were exposed to OGD insult for various time periods up to
6 h as detailed under Materials and methods. Aliquots from the culture media were
taken for LDH releasemeasurements. Values expressed as percent LDH released in theme-
dium out of total culture LDH is mean ± SE (n = 18).*p b 0.05 vs 2 h OGD at each time
point at the respective density. An operational deﬁned range of cell death and duration
of OGD is underlined.
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of cell death in treated versus control PC12 cells was calculated as noted
below.
NP-Index= 1−(% cell death in treated well / % cell death in control
well).
The rescue capacity on a scale of 0–1 is maximal at 1.
2.6. Lipid peroxidation by measurement of TBARS
Malondialdehyde-likemetabolites released into the culturemedium
were collected and reacted with thiobarbituric acid (TBA) reagent as
previously described [12]. Brieﬂy, the TBA reagent was prepared by dis-
solving 0.67% TBA (wt./vol.) and 0.01% (wt./vol.) butylated hydroxytol-
uene (BHT) in 50% acetic acid. Aliquots of 0.5 ml culture medium were
collected after ischemic insult or normoxic conditions and TBA-
reagent (0.5 ml) was added. The solution was heated in boiling water
for 15min. The samples were cooled with tap water and the developed
color read at 535 nm excitation and 553 nm emission using
spectroﬂuorimetry. For quantiﬁcation of TBARS, a standard curve was
prepared by using a 100 μM1,1,3,3-tetraethoxypropane (TEP) stock so-
lution diluted in PBS [12].
2.7. PLX cells metabolic status using the Alamar blue assay
Viability of PLX cell growth in PC12 medium was assessed using the
Alamar Blue assay [13]. Fluorescence in arbitrary units was measured
using spectroﬂuorimetry at an excitation wavelength of 540 nm and
emission wavelength of 595 nm.
2.8. Measurements of IL-6 and VEGF levels using human and mouse selec-
tive ELISA
Aliquots of media from controls (normoxia) or from ischemic PC12
cells or PLX cells as well as co-cultures of both were collected and sub-
mitted to ELISAs selective for human recombinant IL-6 and VEGF165
and for mouse VEGF164, as per the manufacturer's instructions. IL-6
levels were estimated using the quantikine human IL-6 ELISA kit ac-
cording to the manufacturer's instructions. The amount of IL-6 in pg/
ml was calculated from a linear standard curve, with a sensitivity of
3.12 to 300 pg/ml. The anti-IL-6 polyclonal antibody used in the assay
cross-reacted with rat and human IL-6, but shows b0.5% cross-
reactivity with other cytokines and b50% cross-species reactivity was
observed. The samples were also analyzed for human and mouse
VEGF using quantikine human/mouse VEGF ELISA kit according to the
manufacturer's instructions. Using a human VEGF ELISA kit, the amount
of VEGF-A165 in pg/ml was calculated from a human VEGF165 standard
curve, with a sensitivity of 15.6 to 1000 pg/ml. The antibody exhibited
a sensitivity of detection up to N4000 pg/ml and 0.5% cross reactivity
with murine VEGF165. Using a mouse VEGF164 ELISA kit, the amount of
VEGF164 in pg/ml was calculated from a mouse VEGF164 standard
curve, with a sensitivity of 7.8 to 500 pg/ml. The antibody exhibited a
sensitivity of detection up to N2500 pg/ml and 0.2% and 25% cross reac-
tivity with recombinant human VEGF165 and rat VEGF164, respectively.
Preparation of plates and solutions and ELISA protocols was performed
according to the manufacturer's instructions.
2.9. Statistical analysis
Each experiment was performed 3–5 times in sixplicate (n = 6)
wells. The results are presented as mean ± S.E. Statistical comparisons
between experimental groups were determined by using analysis of
variance program (ANOVA) followed by Dunnett's multiple comparison
test. P value of 0.05 or less was considered signiﬁcant for all
comparisons.3. Results
3.1. The impact of PLX cells on PC12 cell death following ischemic insult
In order to optimize the response of the NGF-differentiated PC12
cells to the ischemic insult, we ﬁrst assessed to some detail the effect
of cell density and duration of the OGD exposure on cell death. As
shown in Fig. 1, cell death as assessed by LDH release showed a strong
cell-density and time-of OGD insult dependency which attained a max-
imum at approximately 5 h at an average density of approximately 4
× 105 cells/well. An EC50 value for cell death in the range of 1.6–3.3
× 105 cells/well could be extrapolated and an optimal density of 2
× 105 PC12 cells and was used throughout this study.
We then examined the effect of PLX cells addition on PC12 cell death.
As shown in Fig. 2 (panel A), the presence of PLX cells in the co-culture
system (see drawing) during the OGD phase or during the reperfusion
phase (added after OGD), caused a substantial decrease in cell death
by 46% and 38%, respectively. Addition of the potent antioxidant Tempol
at millimolar concentrations, prior to OGD and throughout reperfusion,
signiﬁcantly reduced cell death by 31%. Tempol was however less effec-
tive when added after the OGD insult, during the reperfusion phase
only. Based on an average cell death value of 39 ± 2% we could extrap-
olate a relative neuroprotective-index (NP-Index) for comparison be-
tween the two agents. Thus as shown in Fig. 2 (panel B), the NP-Index
values of PLX cells and Tempol were 0.45 and 0.31 respectively, when
the agents were present during the entire ischemic insult. When PLX
cells were added during the reperfusion phase only, the NP-Index
remained practically the same suggesting an equally effective rescue ca-
pacity while Tempol failed to provide rescue under these conditions.
These data most likely indicate a different mechanism of protective ac-
tion of these two seemingly different experimental modalities.
The use of PLX cells in this particular co-culture system deemed an
adaptation of cell growth in monolayers as they are usually propagated
in 3D bioreactors on ﬁbrous matrices (3). Therefore we set to examine
their rates of proliferation in the presence of PC12 cell medium compo-
nents. As assessed by the Alamar blue vital stain, at 3 days in vitro, PLX
cell doubling time was highly dependent on the initial amount seeded
and decreased relatively with increasing plating density most likely
due to plating efﬁciency (Table 1). At 6 days, cells still continued to pro-
liferate. These results demonstrate that PLX cells survived and even pro-
liferated in these monolayer conditions. Furthermore, the PLX cells
appeared to be resistant towards the OGD insult applied in this study
(data not shown), similar to the resistance previously reported for
Fig. 2. Effect of PLX cells and Tempol on ischemia-induced PC12 cell death. PC12 cells (2 × 105 cells/well)were seeded in 12-well plates and differentiated for 7 days in the presence of NGF.
Designated wells were supplemented with a platform of PLX cells (2 × 105 cell/insert, see scheme panel A) or 3 mM Tempol before (white bars) or after (gray bars) the 4-h OGD insult.
Cultures were subjected to18 h reperfusion and medium aliquots taken for LDH quantiﬁcation. Cell death expressed as % LDH release out of total LDH (panel A) are mean± SE (n= 30);
*p b 0.01 vs no supplement; **p b 0.01 vs PLX before OGD. Panel B expressed as NP-Index from zero tone was extrapolated from panel A as detailed in Materials and methods.
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vation [14].
The neuroprotective effect of PLX cells on NGF-differentiated PC12
cultures was further evaluated by the appearance of lipid peroxidation
products measured as TBARS, a marker known to increase in PC12
cells after oxidative stress [12,15,16]. As expected, under normoxic con-
ditions, treatment of PC12 cells for 2 h with 0.5 mM H2O2, which was
used as positive control for lipid peroxidation, increased by 2.4 fold
TBARS formation compared to that of untreated controls (Fig. 3).
When subjected to ischemic insult, generation of TBARS in the cell me-
dium increased 1.6 folds. In the presence of PLX cells TBARS were re-
duced (25%) to 0.06 μM/mg protein from a level of 0.081 μM/mg
protein. Tempol on the other hand, did not reduce TBARS levels further-
ing the likelihood of a differentmechanism of action. PLX cells before or
after ischemia released practically the same amounts of TBARS in the
medium (0.055 μM/mg protein— data not shown). Notably, in the pres-
ence of PLX cells, TBARS levels were signiﬁcantly reduced (25%) in the
medium. In contrast, Tempol addition did not reduce the amount of
TBARS generated (2%),
Stem cell intervention for treating the consequences of ischemia is
usually conﬁned to the stage that follows the post traumatic event.
Therefore, it was interesting to evaluate the timewindow for neuropro-
tection upon addition of PLX cells during the reperfusion period (Fig. 4
panels A, B) as well as establish the duration of the neuroprotective ef-
fect during the reperfusion period (Fig. 4 panel C). Our data demon-
strate that addition of PLX cells immediately after OGD insult at the
beginning of the reperfusion period (Fig. 4 panel A), was the most ap-
propriate time to acquire neuroprotection. This is in contrast to Tempol
which basically was ineffective when added after the OGD insult (Fig. 4
panel B). However, when Tempol was added at the beginning of the
OGD insult, it provided neuroprotection even after 3 days followingTable 1
Density-dependent PLX cells proliferation in PC12 growth medium.
Seeding density (×104) Day 3
(FU × 103)
Day 6
(FU × 103)
FU × 103/day
1 3.5 ± 0.08 7.7 ± 0.1 1.1
5 4.0 ± 0.2 8.1 ± 0.2 1.3
10 4.4 ± 0.1 10.5 ± 0.04 1.4
20 6.2 ± 0.08 15.5 ± 0.2 2.0
PLX cells were grown at different densities in PC12 cells medium for 6 days andmetabolic
activity was evaluated by Alamar blue assay at day 3 and day 6 in the samewells. Fluores-
cence in arbitrary units (FU × 103) is presented as mean ± SEM (n = 9). *p b 0.05 vs
day 3.reperfusion, to the same degree as PLX cells did when added at the be-
ginning of the reperfusion phase (Fig. 4 panel C). These results unam-
biguously indicate that the signiﬁcant neuroprotective effect of PLX
cells is sustained during the reperfusion phase for at least 3 days.
Fig. 4 (panel D) illustrates a typical density-dependent neuroprotection
effect of PLX cells with an EC50 corresponding to a cell dose of 6 × 104
PLX cells.
3.2. The neuroprotective effect of PLX cells is mediated by cell-released fac-
tors including IL-6 and VEGF
The effect observed in the presence of PLX cells raised the possibility
that compounds actively or passively released into themedium after is-
chemia are responsible for PC12 cells neuroprotection. Therefore, in
pilot studies variations of conditioned media were collected from cul-
tures exposed to ischemia, and aliquots tested in fresh PC12 cells sub-
jected to ischemia. As shown in Fig. 5 (panel A) a signiﬁcant decrease
in cell death of 25 ± 6%, 25 ± 4% and 52 ± 3% was found upon treat-
ment with either conditioned medium derived from PC12 cells or
from PLX cells alone or from co-cultures of both, respectively. For com-
parison, Tempol reduced PC12 cell death by 31± 3%. TBARS levels were
also reduced by 32% using the ischemic conditionedmedium generated
from PC12/PLX co-cultures (Fig. 5 panel B). These results indicate thatFig. 3. Effects of PLX cells and Tempol on ischemia-induced lipid peroxidation. Experimen-
tal details were identical to those in Fig. 2. Designated wells were supplemented with
3 mM Tempol or 0.5 mM H2O2 (striped bar) before OGD or with PLX cells after 4 h OGD.
After 18 h reperfusion medium aliquots were collected and analyzed for TBARS. Values,
expressed as μM TBARS normalized to mg protein, are mean ± SE (n = 12);*p b 0.05 vs
no supplement in normoxia; **p b 0.01 vs no supplement.
Fig. 4. Cell density and time of treatment dependency of PLX cells and Tempol neuroprotective actions. PC12 cells were exposed for 4 h to OGD and subsequently to different periods of
reperfusion in the presence of PLX cells or 3 mM Tempol as detailed in Fig. 2. Panel A shows % LDH release as mean ± SE (n = 16);*p b 0.01 vs no supplement; **p b 0.01 vs time zero
following supplements at designated time after OGD. Black bars indicate cell death without supplements. Panel B depicts the time course of the NP-Index of PLX cells and Tempol after
OGD and was extrapolated from panel A. Panel C illustrates the long term effects of the supplements on % LDH release (±SE, n = 12) after prolonged reperfusion; *p b 0.05 vs control.
Panel D shows a density-dependence of the NP-Index on the seeding density (log scale) of the PLX cells in the co-cultures. NP-Index value on a scale from zero (no protection) to one
(complete protection) are means ± SE (n = 48);*p b 0.01 compared to ischemia-treated PC12 cells.
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PC12 cells alone and/or in combination, possess the capacity to provide
neuroprotection as noticed by reduced LDH release (cell death) and
TBARS levels (lipid peroxidation).
Prompted by the likelihood thatmesenchymal stem cells as recent-
ly indicated, possess the capacity to secrete several growth factors
[17–19], we set up an ELISA protocol to detect some of these factorsFig. 5. Effect of pre-conditioned medium on LDH release and TBARS production in PC12 cells fo
similar conditions as detailed in Fig. 2 in the presence or absence of 50 μl conditioned media
alone or from PC12/PLX co-culture subjected to OGD. Cell death expressed as % LDH release (pa
medium. Aliquots of the culturemediumwere taken for TBARS determination (panel B) as desc
supplement (normoxia); **p b 0.01 vs no supplement in ischemia.in the current ischemic model. For these studies we applied an anti-
mouse VEGF164 with a partial (15%) cross reactivity to rat VEGF but
no cross reactivity to human VEGF165 and a second, highly selective
human VEGF165 antibody as well as an anti human IL-6 with no cross
reactivity to rat. Fig. 6 depicts the levels of VEGF (panel A) and IL-6
(panel B) in the conditioned medium arising from either PC12 cells
or PLX cells alone or their co-culture under control or ischemicllowing ischemic insult. PC12 cells were exposed to 4 h OGD and 18 h reperfusion under
(added before OGD) which was previously collected from wells of PC12 cells or PLX cells
nel A) are mean± SE (n= 16);*p b 0.01 vs no supplement; **p b 0.01 vs PLX conditioned
ribed in Fig. 3 and expressed as μMTBARS permg protein (±SEM, n= 12);*p b 0.05 vs no
Fig. 6. VEGF and IL-6 identiﬁcation in pre-conditionedmedium following ischemia. PC12 cells were subjected to ischemic or normoxic conditions in the presence or absence of PLX cells as
detailed in Fig. 2. Cultures of PLX cells alone, in the absence of PC12 cells, were also subjected to ischemic or normoxic conditions. Conditionedmediumwas collected and aliquots used for
VEGFmeasurements, using an anti-mouse or a humanMab (panel A) and for IL-6measurements using an anti-humanMab (panel B). Values expressed as pg/mlmedium are mean± SE
(n = 12); *p b 0.01 vs PLX cell normoxia;**p b 0.01 vs PLX cell ischemia.
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crete 110 ± 5 pg/ml VEGF165. This basal value is elevated by nearly 3
fold (315 ± 10 pg/ml) after the ischemic insult. Conditioned medium
derived from PC12/PLX co-cultures after ischemic insult, shows a fur-
ther robust increase up to 1245± 21 pg/ml in VEGF165 indicative for a
strong synergistic effect. Notably, PC12 cells release a basal level, inde-
pendent of ischemia, of rat VEGF. That may suggest that the constitu-
tive rodent levels of VEGF are not sufﬁcient to protect the PC12 cells
after the ischemic insult. Fig. 6 (panel B) also shows a remarkable
basal level of IL-6 secreted from PLX cells as attested by the human
Mab (5.25 ± 2 ng/ml) but only a small increase (about 23%) following
ischemia. In great contrast, an ischemic insult applied to co-cultures of
both PC12 and PLX cells triggered release of IL-6 to a value of approx-
imately 16 ng/ml which constitutes a 4 fold increase over the basal
levels. Taken together, these data strongly indicate that the ischemic
insult episode caused enhanced synthesis and secretion of both
growth factors by the PLX cells and that the presence of the PC12
cells was necessary to trigger the amplitude of this activation.Fig. 7. Effect of VEGF165 and IL-6 supplement and their antagonists on ischemia-induced PC12
combinant human IL-6 (10 ng/ml) or recombinant human VEGF165 (10 ng/ml) or a mixture of
diately after OGD (gray bars). Cell death expressed as % LDH release (panel A) and NP-index (sch
OGD. Panel B depicts the partial neutralization of the protective effect of IL-6 and/or VEGF (stripe
with the IL-6 or Semaxanib (240 ng/ml), a potent VEGFR2 antagonist added 3.5 h before VEGF165
vs no treatment (−); **p b 0.01 vs growth factor alone without antagonist.Further conﬁrmation for the neuroprotective effect of VEGF165 and
IL-6, was obtained fromdirect supplements of either 10 ng/ml of recom-
binant human VEGF165 and/or IL-6 to PC12 cells subjected to ischemia
(Fig. 7 panel A). A robust neuroprotection (NP-Index = 0.35, Fig. 7
panel A, insert) was attained upon treatment of the cultures with either
IL-6 or VEGF165 before or immediately after OGD presumably because
the immediate availability of the growth factors. Interestingly, no syner-
gistic effect was observed upon treating PC12 cells with a combination
of both growth factors. Treatment of the PC12 cultures with human re-
combinant IL-6, VEGF165 and IL-6/VEGF165 in the presence of selective
antagonists, i.e., IL-6 neutralizing monoclonal antibody, VEGF165 recep-
tor 2 antagonist Semaxanib or a combination of both, canceled the
growth factor neuroprotective effect, causing again an increase in cell
death by 33%, 33% and 27%, respectively (Fig. 7 panel B). Treatment of
PC12 cells with antagonists in the absence of agonists had no protective
effects (data not shown).
Further examination on the role of each of these PLX cells-secreted
growth factors prompted us to measure the neuroprotective effect ofcell death. PC12 cells were exposed to ischemia as detailed in Fig. 2 in the presence of re-
both (10 ng/ml each). The growth factors were added 1 min before (white bars) or imme-
eme) aremean± SE (n=20); *p b 0.01 vs no supplement; **p b 0.01 vs IL-6/VEGF before
d bars) by either IL-6 neutralizingmonoclonal antibody (400 ng/ml) added concomitantly
, or amixture of both. Values expressed as % LDH release aremean±SE (n=20). *p b 0.01
Fig. 8. IL-6 monoclonal antibody and Semaxanib reverse the PLX neuroprotective effect on PC12 cells subjected to ischemia. PC12 cells were exposed to ischemia in the presence of PLX
cells, added after OGD, as detailed in Fig. 2. The antagonists including anti-human IL-6 (400 ng/ml), Semaxnib (240 ng/ml) or a mixture of both at the same concentration were added
before OGD. Cell death expressed as % LDH release (panel A) and NP-index (panel B) are mean ± SE (n = 12); *p b 0.01 vs no supplement; **p b 0.05 vs untreated PLX cells.
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shown in Fig. 8 (panels A, B) addition of the IL-6 antibody or administra-
tion of Semaxanib, inhibited the protective effect of PLX cells by 57% and
78%, respectively. A combination of both antagonists, although not syn-
ergistic, was also highly effective (50%). These ﬁndings demonstrate the
involvement of IL-6 and VEGF165 in the PLX-induced neuroprotective
effect.
4. Discussion
This work establishes that human placental expanded (PLX)
mesenchymal-like adherent stromal cells adapted to grow inmonolayer
cultures are able to confer protection to a NGF-differentiated neural cell
line PC12 of pheochromocytoma origin, which has been subjected to an
acute ischemic insult. The ischemic insult triggered by sustained glucose
and oxygen deprivation (OGD) followed by reperfusionwhere both glu-
cose andoxygen level have been replenished, caused robust cell damage
as attested by the release of LDH from the cells into themedium as well
as by production of substantial levels of TBARS, both indicative of oxida-
tive cell damage (Figs. 2 and 3). Notably, a remarkable PLX
concentration-dependent neuroprotective effect was evident (Fig. 4).
During and after the OGD insult, the PLX mesenchymal-like adher-
ent stromal cells, secrete into the culture medium at least two growth
factors, IL-6 and VEGF, that have been identiﬁed and characterized. Sev-
eral lines of evidence are indicative for the involvement of these factors
in the rescue process of PC12 cells. Firstly, the PLX cells and not the PC12
cells actively secrete both factors into the growth medium upon ische-
mia as assessed by a highly sensitive and speciﬁc immunoassay
(Fig. 6). Interestingly, the relatively high level of the basal rodent
VEGF compared to human VEGF after ischemia is fairly striking
(Fig. 6A); yet the rodent VEGF is neither enhanced nor able to provide
protection to the PC12 cells. That may be reasoned by a difference in
the afﬁnities of the rodent and human VEGF or that additional VEGF,
above the basal levels, is needed to enable neuroprotection. Secondly,
direct addition of human recombinant VEGF or IL-6 at nanogram con-
centrations was able to reproduce the neuroprotective effect obtained
in the PLX/PC12 co-culture system (Fig. 7). Thirdly, inhibition of IL-6
and VEGF neuroprotective activity by speciﬁc antagonists was attained
to either exogenously added peptide.
Mesenchymal stem cells have been shown recently to secrete a vari-
ety of protective anti-inﬂammatory cytokines and growth factors and
also exert a protective capacity in vivo in stroke therapy [17–19] and
in traumatic brain injury [20–22]. In line with these studies,implantation of PLX cells in a mousemodel of critical limb ischemia, re-
duced ischemic damage as expressed by improved blood ﬂow to the
damaged limb, increased capillary density, decreased oxidative stress
and endothelial damage and increased functionality of the insulted
limb [3].
We have expanded these observations to a neuronal cell line model
and now demonstrate that PLX cells can secrete such growth factors
undermonolayer culture conditions. This is the ﬁrst time, to our knowl-
edge, that such capability of the PLX cells in monolayer cultures to se-
crete ex vivo speciﬁc growth factors has been reported. The use of co-
cultures offers the unique opportunity to investigate cell–cell interac-
tion events mediated via the medium under amenable conditions. In
that respect, we ﬁrstly show that there is a reciprocal interaction be-
tween the ischemia-targeted PC12 cells and the potency of the PLX
mesenchymal-like adherent stromal cells to enhance secretion
(Fig. 5). This is clearly evident from the fact that OGD-insulted PLX
cells alone show little but signiﬁcant enhanced secretory activity. Fur-
thermore, the dependency of PLX cell secretion by PC12 cells highly sug-
gests a possible release of active substances and/or low molecular
weight signals from the ischemically-insulted PC12 cells. The nature of
these substances is presently unknown. In this context it is possible
that the protective activity of the PC12 conditioned medium alone
(Fig. 5) is due to certain factors released by the PC12 cells which are
beneﬁcial. Secondly, the time window of the stimulation of release ap-
pears to be fairly large, provided cells are sufﬁciently close to the time
of the OGD insult (i.e. 30 min, see Fig. 4 panel A). The inability of PLX
cells to rescue PC12 cells after a certain time point (Fig. 4 panels A, B),
could be attributed to the fact that triggering molecules arising
from the PC12 cells i.e. release of ATP [10] or anti-oxidants [6] are
rendered cryptic, such that within a short period (1 h), PLX cells are
unable to secrete growth factors. This raises the importance of identify-
ing the therapeutic window for the use of these cells for in vivo
transplantation.
Thirdly, we provide solid evidence that a neurally-differentiated
cell line under the inﬂuence of NGF appears robustly responsive to
cues and signals which are derived from a stem cell line, but also ap-
pear to inﬂuence the latter. Indeed stem cells secrete a broad spec-
trum of signaling molecules but these are likely to be highly
selective and quantitatively controlled depending on the micro envi-
ronmental cues that the target cells confer in their domains. Thus
stem cells challenged with cues from kidney or heart may provide a
different spectrum of growth factors than those challenged by brain
or other peripheral tissues. Such an advantage should be underscored
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tors, the latter of which are of transient nature.
The molecular mechanism underlying the neuroprotective effects
still remains elusive and several second messenger pathways have
been implicated but not completely elaborated. Some laboratories sug-
gested that the neuroprotective effects are mediated by attenuation of
the excessive calcium inﬂux, a primary trigger for excitotoxic cascade
during ischemic insult and/or inhibition of stress kinases such as Jnk
and p-38 [23,24]. Other studies indicate a mechanism of action which
includes modulation of free ROS and up regulation of cellular signaling
cascades [25]. The latter possibility is also supported by recent studies
from our laboratory indicating that cord blood derived neuronal pro-
genitors confer neuroprotection following a robust reduction of ROS
level and secretion of different anti-oxidant molecules into the culture
medium [6]. Moreover mesenchymal cells derived from various origins,
provide rescue to PC12 cells from diverse cytotoxic insults such as
hydrogen peroxide, radiation, chronic ethanol damage and hypoxia
via downregulation of apoptotic proteins and upregulation of PI3K/Akt
kinase pathway [26–30].
In this report we provide substantial evidence that IL-6 and VEGF165
constitute a major mechanism involved in PC12 cell neuroprotection
from ischemic insult. IL-6 in particular, appears beneﬁcial in preventing
death in PC12 cells for it has been shown to rise in a spectrum of stress
events such as serum deprivation or addition of toxic agents such as cal-
cium ionophore [31,32], 6-hydroxydopamine, 4-hydroxynonenal [33,34]
andMPP+or tetrahydro-isoquinoline [35]. In all these studies reduction
of the oxidative damage has been attributed to activation of free radical
detoxifying mechanisms such as catalase [34] and glutathione levels
[33] possibly accompanied by upregulation of phosphorylation path-
ways such as phosphatidylinositol 3-kinase/Akt and STAT3 [31].
VEGF165 on the other hand, apart from being amajor angiogenic fac-
tor, is also known for its neurotropic activity in PC12 cells [36] after
beta-amyloid [37], glutamate [28] and hypoxia-induced [27] toxicity.
VEGF is also beneﬁcial in OGD insult applied to primary cultures of rat
neurons [38,39] and in rat model of cerebral ischemia [40]. These tro-
phic effects are believed to be mediated through the PI3K/Akt/FoxO1
survival pathway [27,28,38].
In this study we took advantage of the well-established antioxidant
Tempol [41,42] as a comparative, positive marker for its antioxidant
characteristics. Clearly, protection by Tempol appears to be attained
through a different mechanism as attested by its shorter window of op-
portunities to provide rescue to cells (Figs. 2 and 4) and by its continu-
ous presence at relatively high millimolar concentrations. Nevertheless
it was instrumental in determining themagnitude of protection in com-
parison to the PLX cells.
Considering that at this time PLX cells constitute an important tool in
clinical trials for therapy of different ischemic disorders, it would be
tempting to propose that the principal mode of action of these cells in-
volves the active secretion of IL-6 and VEGF165. This possibility is plausi-
ble since mesenchymal stem cell transplantation has been shown to be
beneﬁcial in ischemic disorders via trophic mechanisms [43,44]. Trophic
support is generally of transient nature as opposed to a cell substitution
mechanism and is relatively fast and diminished proportionally to the
survival rate of the transplant [45]. A large variety of trophic factors,
which may be beneﬁcial to injured and/or regenerating neurons, have
been detected and isolated from secreted proteomes derived of human
MSC fetal and adult tissues including placenta, umbilical cord blood, um-
bilical stroma, adult bone marrow, and peripheral blood [46,47].
In conclusion, PLX-induced neuroprotection towards NGF-
differentiated PC12 cells exposed to ischemia is strongly correlated
to secretion of IL-6 and VEGF165 which is in line with the neuroprotec-
tive effect of these factors in hypoxic/ischemic injuries both in vitro
and in vivo models [48,49]. Therefore, this correlation may explain
part of the neuroprotective mechanism of PLX cells upon transplanta-
tion in ischemic models [2,3]. Furthermore, our present studies add to
the notion that pre-triggering of PLX cells before transplantation mayenhance the effectiveness of the stem cell therapy [44,50]. Future in-
vestigations on the secretome of PLX cells, should reveal additional
anti-inﬂammatory cytokines and/or growth factors with neuropro-
tective effects beneﬁcial for treating ischemic disorders.
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